SK Pharmteco Capabilities Update July 2026: Gene Therapy

Standardizing viral vector manufacturing without sacrificing application flexibility remains a central challenge for cell and gene therapy developers. Fixed, one-size-fits-all production platforms often force unnecessary cost burdens on small-volume rare disease indications, or struggle to achieve the stringent purity profiles required for direct in vivo administration. Utilizing modular, scalable platforms enables biopharma innovators to customize processes according to targeted routes of delivery.

For instance, high-purity in vivo therapies—such as ocular or central nervous system indications—can optimize downstream purification to achieve over 90% full capsids at a 50-liter scale. Conversely, systemic treatments requiring high viral genome outputs can seamlessly scale to 500 liters or beyond in suspension. Integrating adaptive downstream operations with specialized nucleases and secondary polishing steps ensures drug-product-level purity for in vivo lentivirus, while streamlined chromatography hybrid models deliver downstream recoveries up to 85% for adenoviral vectors. Implementing tailored viral vector strategies significantly compresses timelines, de-risking the path from transgene design to clinical supply.